Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
Study subjects will have A-100 ADP measurements performed at baseline and after initiation of P2Y12 inhibitor antiplatelet therapy, following loading and maintenance doses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Enrollment
280
Administration of P2Y12 inhibitor antiplatelet therapy
Blood is drawn for testing of platelet aggregation activity
Change in Platelet Activity Index (PAI)
Platelet reactivity measurement using A-100 ADP assay
Time frame: Baseline, day 1, day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.